Yueyin Pan

机构：University of Science and Technology of China, Hefei University of Technology · ORCID：0000-0003-0532-5368

发表论文 234 篇 · 总被引 9496 次 · h-index 41

代表论文

• Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment (2025 · Molecular Cancer · 被引 63)
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)
• Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 16)
• Unraveling breast cancer response to neoadjuvant chemotherapy through integrated genomic, transcriptomic, and circulating tumor DNA analysis (2025 · Breast Cancer Research · 被引 9)
• Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 8)
• First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial (2025 · The Lancet Respiratory Medicine · 被引 7)